Bijal D. Shah, MD

Experts in hematologic malignancies conclude their discussion by discussing BTK degraders and other targets in the treatment of mantle cell lymphoma.

A comprehensive look at the role of bispecific antibodies, including glofitamab, in the treatment of mantle cell lymphoma.

Bijal D. Shah, MD, and Matthew J. Matasar, MD, discuss how they approach treating patients with MCL who rapidly progress on BTK inhibitors.

A panel of experts in hematologic malignancies analyze clinical studies and real-world data of brexucabtagene autoleucel in mantle cell lymphoma.

Alexey V. Danilov, MD, PhD, presents a second patient profile of a 60-year-old patient with MCL, and the panel discusses using CAR T-cell therapy to treat MCL.

A comprehensive discussion on ways to approach treating patients with high-risk mantle cell lymphoma.

A detailed look at how to select the appropriate BTK inhibitor to treat patients with MCL and the potential role of the non-covalent BTK inhibitor pirtobrutinib in MCL.

Experts in hematologic malignancies review the role of BTK inhibitors and other therapies in patients with relapsed/refractory mantle cell lymphoma.

A panel of experts in hematologic malignancies discuss the SHINE study, which looked at ibrutinib with bendamustine and rituximab in elderly patients with MCL.

Matthew J. Matasar, MD, discusses the prospect of using minimal residual disease to guide treatment decisions in mantle cell lymphoma.

Boyu Hu, MD, and Bijal D. Shah, MD, provide their thoughts on the TRIANGLE study looking at ibrutinib versus stem cell transplant in MCL.

A patient profile of a 74-year-old man diagnosed with mantle cell lymphoma who receives treatment with a non-covalent BTK inhibitor is presented by Alexey V. Danilov, MD, PhD.

Alexey V. Danilov, MD, PhD, provides an overview of the pathophysiology, symptoms, and subtypes of mantle cell lymphoma.

Bijal D. Shah, MD, MS, discusses the survival analysis of subgroups of patients with relapsed/refractory B-cell acute lymphoblastic leukemia treated in the phase 3 ZUMA-3 trial.

Closing out their discussion on B-cell malignancies, expert panelists share clinical pearls on the management of marginal zone lymphoma.

A comprehensive review of novel therapies in relapsed/refractory marginal zone lymphoma and possible sequencing strategies in this setting.

Shared insight on frontline treatment approaches for patients diagnosed with marginal zone lymphoma.

Clinical pearls for community physicians regarding the optimal management of patients with follicular lymphoma.

Panelists use an illustrative clinical case to comprehensively discuss the selection and sequencing of therapies for patients with follicular lymphoma.

A review of the role of PI3K inhibitors in the treatment of follicular lymphoma, and how they have been used to improve patient outcomes.

Expert perspectives on novel approaches to treatment in the relapsed/refractory setting, particularly CAR T-cell therapy, for patients with follicular lymphoma.

Shared insight on the indolent nature of follicular lymphoma and frontline therapy options for this disease.

Closing out their discussion on mantle cell lymphoma, expert panelists share clinical pearls for practicing community physicians.

Panelists use an illustrative clinical case to highlight best practices in sequencing therapy for mantle cell lymphoma and discuss novel combination strategies under investigation.

A brief review of CAR T-cell therapy in relapsed/refractory mantle cell lymphoma as studied in the ZUMA-2 clinical trial of brexucabtagene autoleucel.

Moving to second-line therapy for mantle cell lymphoma, experts discuss available BTK inhibitors, including the novel agent pirtobrutinib.

Shared insight on the optimal selection and use of frontline therapy for patients who present with mantle cell lymphoma.

Expert panelists discuss a number of recent updates in B-cell lymphoma, particularly mantle cell lymphoma, follicular lymphoma and marginal zone lymphoma, that were presented at key conferences in 2021.

Bijal Shah, MD, MS, discusses the FDA approval of brexucabtagne autoleucel in relapsed/refractory B-cell acute lymphoblastic leukemia.